|
MechanismIGF-1R antagonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date21 Jan 2020 |
Phase 1, Open-Label Safety and Pharmacodynamic Study of RV001, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist, Administered by Intravenous (IV) Infusion in Patients With Diabetic Macular Edema (DME)
A Phase 1 Study to evaluate the Safety of teprotumumab in Patients with Diabetic Macular Edema.
100 Clinical Results associated with River Vision Development Corp.
0 Patents (Medical) associated with River Vision Development Corp.
100 Deals associated with River Vision Development Corp.
100 Translational Medicine associated with River Vision Development Corp.